Friday 6 November 2026 Export ASND’s income statement to Excel — free account

Ascendis Pharma A/S

Ascendis Pharma A/S’s revenue for fiscal 2025 (year ended December 2025) was $814.8 million, up 107.1% from fiscal 2024.

Revenue: +119.9%
EPS: +612.3%
Free cash flow: +2,335.9%
Total debt: −41.8%

Quarter to June 2026, against a year earlier

256.42 2.97 +1.17%

Follow ASND

Alert me

Market cap: $16.6B
P/E: 18.3×
Fwd P/E: 15.4×
Dividend yield: —
F-score: 5/9
Altman Z: 2.02
Beneish M: −2.51
Dividend safety: n/a

Overview

Ascendis Pharma A/S (ASND) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Ascendis Pharma A/S (ASND) trades at a P/S ratio of 13.5×. Over the past ten years it has ranged from 0.0× (September 2015) to 7,054× (October 2018); the current reading is higher than 8% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/ASND/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Ascendis Pharma A/S P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/ASND/metrics/ps-ratio">Ascendis Pharma A/S (ASND) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	15.9×	(21.68%)
FY2024	20.3×	(18.55%)
FY2023	24.9×	(80.19%)
FY2022	126×	(84.32%)
FY2021	801×	(24.67%)
FY2020	1,063×	146.09%
FY2019	432×	109.69%
FY2018	206×	(73.38%)
FY2017	774×	645.78%
FY2016	104×	114.83%

Period	P/S ratio	Change
Jun 2026	14.2×	0.06%
Mar 2026	14.2×	(10.79%)
Dec 2025	15.9×	(5.12%)
Sep 2025	16.7×	(14.06%)
42 more quarters	Free account

Against its own ten years

Low 0.0× High 7,054×

Ten-year median 134×

Current reading's percentile 2

Company	P/S ratio
JAZZ Jazz Pharmaceuticals PLC compare	3.1×
ALNY Alnylam Pharmaceuticals, Inc. compare	4.2×
EXEL Exelixis, Inc. compare	6.8×
HALO Halozyme Therapeutics, Inc. compare	7.8×
BNTX BioNTech SE Sponsored ADR compare	7.9×
ASND Ascendis Pharma A/S	13.5×
BBIO BridgeBio Pharma, Inc. compare	15.5×
INSM Insmed, Inc. compare	15.6×
SMMT Summit Therapeutics PLC compare	15,884×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Ascendis Pharma A/S (ASND) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on ASND

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on ASND

Stockrow Weekly